Trial Results Update: The COMMIT Study (NRG-GI004/SWOG-S1610)

03/17/2026

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR/MSI-H Immuno-therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-high (MSI-H) Metastatic Colorectal Cancer

Results from the COMMIT study (NRG-GI004/SWOG-S1610) were recently presented by Dr. Caio Rocha Lima at the 2026 ASCO Gastrointestinal Cancers Symposium and again during the Scientific Session at the NRG Oncology Winter 2026 Meeting, both held in San Francisco in January. The COMMIT study demonstrated that the combination of FOLFOX-bevacizumab-atezolizumab led to a significantly longer progression free survival than atezolizumab monotherapy in the first line setting for dMMR metastatic colorectal cancer. Overall survival was no different and longer-term follow-up is ongoing. Toxicity was increased for those receiving multi-agent therapy, but no new safety signals were identified. Importantly, the experimental arm of FOLFOX-bevacizumab-atezolizumab had notable disease control early, suggesting this treatment may be most beneficial for those patients with bulky or aggressive disease.

Although the trial closed to enrollment earlier than planned, its findings continue to underscore the critical role of the NCTN groups in advancing the care of patients with colorectal cancer and driving progress in treatment for this disease.